A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections

The Journal of Antimicrobial Chemotherapy
S MehtarE W Taylor

Abstract

We conducted a prospective, multi-centre, open, randomized study in 11 UK hospitals to compare iv meropenem 1 g tds with the combination of iv cefotaxime 1 g tds and iv metronidazole 500 mg tds in patients with serious infections. One hundred and sixty-one patients were enrolled, of whom 131 were clinically evaluable (meropenem, n = 68; cefotaxime/metronidazole, n = 63). The most common infections were subsequent to intra-abdominal pathology (meropenem, n = 77%; cefotaxime/metronidazole, n = 75%), and were usually accompanied by septicaemia (meropenem, n = 61%; cefotaxime/metronidazole, n = 53%). The incidence of a satisfactory clinical response was similar in the two groups at the end of treatment (93% for meropenem; 92% for cefotaxime/metronidazole) and up to 8 weeks later (96% for meropenem; 93% for cefotaxime/metronidazole). Satisfactory bacteriological response (success or presumed success) was recorded at the end of therapy in 86% of meropenem and 88% of cefotaxime/metronidazole patients. Adverse events were reported in 32% of meropenem and 25% of cefotaxime/metronidazole patients, and most were mild or moderate and did not require discontinuation of therapy. Twenty-one patients (ten meropenem and 11 cefotaxime/metronidaz...Continue Reading

Citations

Aug 26, 1998·International Journal of Antimicrobial Agents·B A Cunha
Jan 25, 2003·Surgical Infections·John E MazuskiUNKNOWN Therapeutic Agents Committee of the Surgical Infections Society
Nov 16, 2004·Critical Care Medicine·Pierre-Yves BochudThierry Calandra
Dec 6, 2008·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Philip ToltzisJeffrey Blumer
Jul 6, 2012·Clinical Microbiology Reviews·Pranita D TammaLisa L Maragakis
Oct 3, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joseph S SolomkinUNKNOWN Infectious Diseases Society of America
Apr 20, 2014·The Journal of Antimicrobial Chemotherapy·Joan P CannonShellee A Grim
Mar 13, 2008·Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen·P KujathA Rodloff
Dec 19, 2009·Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen·K-F Bodmann, UNKNOWN und die Expertenkommission der Infektliga
Jun 25, 1999·Scandinavian Journal of Infectious Diseases·S R Norrby, K M Gildon
Mar 29, 2011·Critical Care Clinics·Cybéle L AbadNasia Safdar
Mar 10, 2001·Journal of Chemotherapy·F Alvarez Lerma, UNKNOWN Serious Infection Study Group
Oct 12, 2005·Archives of Medical Research·M Sigfrido Rangel-Frausto
Jan 30, 2007·Expert Opinion on Pharmacotherapy·Ioannis P KioumisDavid P Nicolau
Oct 22, 2008·Expert Opinion on Pharmacotherapy·Diogo Diniz Gomes BuganoEliezer Silva
Dec 3, 2014·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hiroshige MikamoMasahito Nagashima
May 10, 2007·Drugs·George G ZhanelJames A Karlowsky
Apr 23, 2005·The Cochrane Database of Systematic Reviews·P F WongD J Leaper
Dec 29, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Xiuwen WuJianan Ren

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.